27146-12-9

Basic information

• Product Name: 2-(2-Furyl)-5-nitrobenziMidazole, 95%
• Synonyms: 2-(2-Furyl)-5-nitrobenziMidazole, 95%;2-(2-furanyl)-6-nitro-1H-benzimidazole;2-Furan-2-yl-5-nitro-1H-benzoimidazole;2-(2-Furyl)-6-nitrobenzimidazole
• CAS NO: 27146-12-9
• Molecular Formula: C11H7N3O3
• Molecular Weight: 229.19158
• Mol File: 27146-12-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 228-229 °C(Solv: nitromethane (75-52-5))
• Boiling Point: 473.5±43.0 °C(Predicted)
• Appearance: /
• Density: 1.478±0.06 g/cm3(Predicted)
• PKA: 9.43±0.10(Predicted)
• CAS DataBase Reference: 2-(2-Furyl)-5-nitrobenziMidazole, 95%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Furyl)-5-nitrobenziMidazole, 95%(27146-12-9)
• EPA Substance Registry System: 2-(2-Furyl)-5-nitrobenziMidazole, 95%(27146-12-9)

Safety Data

• Hazardous Substances Data: 27146-12-9(Hazardous Substances Data)

Usage

Purity

95%

Molecular Weight

178.16 g/mol

Appearance

Pale yellow solid

Solubility

Slightly soluble in water, soluble in common organic solvents

Melting Point

240-245°C

Boiling Point

Not applicable, as it is a solid

Functional Groups

Nitro group, furyl substituent, benzimidazole core

Synthesis

Derived from benzimidazole through chemical reactions involving the addition of a nitro group and a furyl substituent

Uses

Utilized in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals

Pharmacological and Biological Activities

Known for its potential pharmacological and biological activities

Safety

Handle with care and follow proper safety protocols due to potential health and environmental hazards.

Upstream product

• 98-01-1 furfural 
• 99-56-9 4-Nitrophenylene-1,2-diamine 

Downstream Products

• 37128-74-8 2-(furan-2-yl)-1H-1,3-benzodiazol-5-amine 
• 56119-96-1 2-furan-2-yl-7-methyl-1(3),6-dihydro-imidazo[4,5-f]quinolin-9-one 

Relevant articles and documents

Synthesis and Reactivity of Fusion Product of 2-Methylthiazole Fragment to 2-(Furan-2-yl)benzimidazole

Reaction of 1,2-diamino-4-nitrobenzene with furan-2-carbaldehyde in the presence of copper sulfate afforded 2-(furan-2-yl)-5(6)-nitro-1H-benzimidazole. Its N-methylation provided 1-methyl-5(6)-nitro isomers. After reduction of isomers with tin in conc. HCl a pure 3-methyl-2-(furan-2-yl)benzimidazol-5-amine was obtained. The condensation of this amine with acetic anhydride led to the formation of N-[3-methyl-2-(furan-2-yl)benzimidazol-5-yl]acetamide whose treatment with excess P2S5 in anhydrous pyridine resulted in the corresponding thioamide. The latter was oxidized with K3[Fe(CN)6] in alkaline environment to obtain 2,8-dimethyl-7-(furan-2-yl)-8H-imidazo[4,5-g][1,3]benzothiazole. Its reactions of electrophilic substitution were studied: nitration, bromination, sulfonation, formylation, acylation. The substituent is introduced exclusively in the position 5 of the furan ring.

COMPOSITION FOR INHIBITING SYNTHESIS OF MYCOTOXIN WITHOUT AFFECTING THE GROWTH OF THE FUNGI

A composition for inhibiting the growth of mycotoxins without affecting the growth of fungi is provided. The mycotoxin is an Aflatoxin and the fungus is an Aspergillus. The anti-aflatoxin composition comprises benzimidazole derivatives of Formula, where the A is hydrogen or C1-C6 alkyl or C6-C14 aryl; B is C1-C10 alkyl or C6-C14 aryl or oxygen, sulfur, nitrogen containing heteroaryl; C and D are hydrogen or C1-C6 alkyl or C1-C6 alkoxyl or C6-C14 aryl; E is hydrogen or nitro or cyano or carboxyl or acetamidoxime or amidoxime or C1-C6 alkyl or C1-C6 alkoxyl or C6-C14 aryl or oxygen, sulfur, and nitrogen containing heteroaryl; F is hydrogen or C1-C6 alkyl or C1-C6 alkoxyl or C6-C14 aryl or oxygen, sulfur, and nitrogen containing heteroaryl, and mixture thereof with corresponding salts.

SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[l,5-a]pyrimidine compounds described herein include 5,7- dimethyl-N-phenylpyrazolo[l,5-a]pyrimidine-3-carboxamide compounds and variants thereof.